{"id":1112,"date":"2020-09-24T09:42:51","date_gmt":"2020-09-24T16:42:51","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=1112"},"modified":"2020-09-25T09:45:00","modified_gmt":"2020-09-25T16:45:00","slug":"performance-characteristics-of-five-immunoassays-for-sars-cov-2-a-head-to-head-benchmark-comparison","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/24\/performance-characteristics-of-five-immunoassays-for-sars-cov-2-a-head-to-head-benchmark-comparison\/","title":{"rendered":"Performance Characteristics of Five Immunoassays for SARS-CoV-2: A Head-to-Head Benchmark Comparison"},"content":{"rendered":"<ul>\n<li>Four commercial and widely available SARS-CoV-2 IgG assays (Abott, DiaSorine, Roche, and Siemens), and a novel immunoassay (Oxford) were evaluated for performance using identical sample sets. All assays achieved a sensitivity \u226598% and specificity\u226598% on samples taken 30 days or more post-symptom onset, based on 976 pre-pandemic blood samples collected in 2014-2016 and 536 blood samples collected from lab-confirmed COVID-19 patients.<\/li>\n<\/ul>\n<p>Ainsworth et al. (Sept 23, 2020). Performance Characteristics of Five Immunoassays for SARS-CoV-2: A Head-to-Head Benchmark Comparison. The Lancet Infectious Diseases. <a href=\"https:\/\/doi.org\/10.1016\/S1473-3099(20)30634-4\">https:\/\/doi.org\/10.1016\/S1473-3099(20)30634-4<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Four commercial and widely available SARS-CoV-2 IgG assays (Abott, DiaSorine, Roche, and Siemens), and a novel immunoassay (Oxford) were evaluated for performance using identical sample sets. All assays achieved a sensitivity \u226598% and specificity\u226598% on samples taken 30 days or more post-symptom onset, based on 976 pre-pandemic blood samples collected in 2014-2016 and 536 blood&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/24\/performance-characteristics-of-five-immunoassays-for-sars-cov-2-a-head-to-head-benchmark-comparison\/\">Read more<\/a><\/div>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[27],"topic":[19],"class_list":["post-1112","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-testing","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=1112"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1112\/revisions"}],"predecessor-version":[{"id":1113,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1112\/revisions\/1113"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=1112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=1112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=1112"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=1112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}